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Abstract
I propose novel partial identification bounds on disease prevalence from information on
test rate and test yield. The approach broadly follows recent work by Manski and Moli-
nari (2020) on COVID-19, but starts from user-specified bounds on (i) test accuracy, in
particular sensitivity, (ii) the extent to which tests are targeted, formalized as restriction
on the effect of true status on the odds ratio of getting tested and thereby embeddable
in logit specifications. The motivating application is to the COVID-19 pandemic but the
strategy may also be useful elsewhere.
Evaluated on data from the pandemic’s early stage, even the weakest of the novel
bounds are reasonably informative. For example, they place the infection fatality rate for
Italy well above the one of influenza by mid-April.
∗Thanks to Chuck Manski and Francesca Molinari for lively discussions and for sharing their data, to Dan
Sacks and Coady Wing for feedback and literature pointers, and to Cynthia Stoye for special support in crazy
times. Any and all errors are mine.
†Department of Economics, Cornell University, stoye@cornell.edu.
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1 Introduction
Prevalence of a novel disease like COVID-19 is a quintessential missing data problem: Only
a small subset of the population has been tested, this subset is almost certainly selective, we
do not even know the sensitivity of our tests, and our understanding of the pandemic is vague
enough so that we might not want to overly rely on heavily parameterized models. This is a
natural application for partial identification analysis, i.e. the analysis of bounds on parameter
values that can be inferred from imperfect data and weak but credible assumptions, without
forcing statistical identifiability of a model.1 In work that is already proving influential,
Manski and Molinari (2020, MM henceforth) bring this analysis to prevalence estimation and
illustrate one way to carry it out. I build on their work to propose a general framework
for analyzing partial identification of disease prevalence, assuming that one has partially
identifying information on the selectivity and sensitivity of diagnostic tests.
I strongly agree with the overall thrust of MM. I deviate from their approach because
I refine worst-case bounds by placing a priori restrictions on test sensitivity and selectivity
but not on negative predictive value (all terms will be defined later). These restriction are
arguably somewhat easy to relate to other literatures, and – unlike with the negative pre-
dictive value – bounds on them can be asserted independently of prior bounds on prevalence
itself. In the empirical application, bounds that only restrict the direction of selectivity are
considerably more informative than the analogous bounds emphasized in MM, and yet I will
argue that assumptions became more compelling. Bounds become much tighter if one decides
to substantively restrict selectivity, though the fair comparison then is to other, also tighter,
bounds in MM.
2 The Identification Problem
2.1 Basic Setting and Worst-Case Bounds
Consider first the problem of bounding prevalence of a disease in a stylized example where
one has observed test rate and test yield for one population. I will call the disease COVID-19
henceforth but the ideas are obviously more general.
Thus, let C indicate true infection status (with C = 1 indicating infection), T test status
(with T = 1 indicating having been tested), and R test result (with R = 1 a positive test
result; we observe R only conditionally on T = 1). In particular, define the testing rate
τ = Pr(T = 1) and the test yield γ = Pr(R = 1|T = 1). These objects are directly identified
from the data, and we will assume that they are known; indeed, we abstract from inference
theory throughout. We also maintain the assumption that (PCR-)tests for COVID-19 have
specificity (=true negative rate Pr(R = 0|T = 1, C = 0)) of 1; thus, Pr(C = 1|R = 1) = 1.
1See Manski (2003) for an early monograph and Molinari (2020) for an extensive survey.
[2]
Generalizing away from this simplification would be straightforward.
Worst-case bounds on the true infection rate can then be derived from the Law of Total
Probability and the logical bound on [0, 1] on any unknown probability. In particular, write
Pr(C = 1) = Pr(C = 1|R = 1) Pr(R = 1) + Pr(C = 1|R = 0) Pr(R = 0)
and observe that Pr(C = 1|R = 0) ∈ [0, 1], whereas Pr(R = 1) = γτ and Pr(C = 1|R = 1) = 1
by maintained assumption. Thus, without any further assumption,
Pr(C = 1) ∈ [γτ, 1]. (2.1)
These bounds go back to Manski (1989) in spirit and are also the starting point of MM. I
next lay out novel ways to refine them.
2.2 Introducing Bounds on Sensitivity and Selectivity of Tests
I propose to refine (2.1) by asserting bounds on test sensitivity (i.e., true positive rate Pr(R =
1|C = 1)) and on test selectivity (i.e., the relation of Pr(T = 1|C = 1) to Pr(T = 1|C = 0) but
not either of these two probabilites by itself). I do not claim that any of these are context-
independent, much less known; hence, prior information will be used in form of bounds.
However, test sensitivity relates directly to a large medical literature, and test selectivity can
be easily related to econometric models of binary response. I next explain the approach and
work out its implications.
Refinement: Allow for measurement error through bounding sensitivity. Sensi-
tivity is a parameter that medical experts think about a lot. as will be discussed later, it is
also the target parameter in much research on COVID-19.
Thus, consider:
Assumption 1: Sensitivity of the test is bounded by
Pr(R = 1|C = 1) =: pi ∈ [pi, pi]. (2.2)
The effect of Assumption 1 on prevalence bounds is easily calculated.
Proposition 1: Suppose Assumption 1 holds. Then:
Pr(C = 1) ∈ [γτ/pi, γτ/pi + 1− τ ]. (2.3)
Proof. Write
Pr(C = 1) = Pr(C = 1|T = 1) Pr(T = 1) + Pr(C = 1|T = 0) Pr(T = 1). (2.4)
[3]
While no informative bound on Pr(C = 1|T = 0) is available, we have
Pr(R = 1|T = 1)
= Pr(R = 1|C = 1, T = 1) Pr(C = 1|T = 1) + Pr(R = 0|C = 1, T = 1)︸ ︷︷ ︸
=0 by assumption
Pr(C = 0|T = 1)
= Pr(R = 1|T = 1, C = 1)︸ ︷︷ ︸
=pi
Pr(C = 1|T = 1),
implying (in the notation introduced above) that Pr(C = 1|T = 1) = γ/pi ∈ [γ/pi, γ/pi]. The
bounds follow by substituting into (2.4).
Remark 2.1: This result is easily extended to allow for specificity (=true negative rate
Pr(R = 0|C = 0, T = 1)) to differ from 1. Indeed, the bounds simply adjust prevalence
in the tested population through the well-known formula “prevalence=(yield+specificity-
1)/(sensitivity+specificity-1)” and leave prevalence in the untested population unconstrained.
This is not worked out to economize on notation.
Refinement: A “logit bound” on test selectivity. Consider also the following:
Assumption 2: The factor κ in
Pr(T = 1|C = 1)
1− Pr(T = 1|C = 1) = κ
Pr(T = 1|C = 0)
1− Pr(T = 1|C = 0)
can be bounded as κ ∈ [κ, κ].
Assumption 2 bounds the relative odds ratio of being tested between true positives and
true negatives. Of course, this is only one of many possible ways to constrain how targeted
tests are. Considerations in favor of Assumption 2 are:
• In principle, bounds on κ can be asserted independently of any knowledge of, or bounds
on, either prevalence ρ or empirical test rate τ . This contrasts with the superficially
simpler strategy of asserting bounds on Pr(T = 1|C = 1)/Pr(T = 1|C = 0). The latter
quantity is bounded above by (1−ρ)/(τ −ρ), so that plausibility of an upper bound on
it will depend on ideas on those other quantities. Similarly, Pr(C = 1|T = 1)/Pr(C =
1|T = 0) depends on τ and ρ. While one may plausibly restrict this fraction to exceed
1 (this is the test monotonicity in MM), it may be difficult to convincingly assert a
tighter bound.
• The bound is easily related to models of selection. In particular, bounding κ in the
above is equivalent to bounding it in the logit model
Pr(T = 1|C = c) = exp(α+ κc)
1 + exp(α+ κc)
.
[4]
Logit models are well understood in econometrics and medical statistics, so this con-
nection generates an interface to natural estimation strategies and maybe researcher
intuitions about plausible parameter values. Also, if covariates are included in the
above logit, the equivalence is maintained conditionally on covariates (with the κ con-
stant across covariates).
The selectivity factor κ could be bounded from both above and below. In this paper’s appli-
cation, I will impose throughout that κ ≥ 1, thus there is at least weak selection of infected
subjects into testing, and I will consider values of κ that force strict selection. Bounding
selectivity from above, or also allowing for a lower bound below 1, may be interesting in
other contexts, for example, if getting tested is stigmatized or tests are targeted but not at
the at-risk population.
The implications of bounding κ are slightly more involved.
Proposition 2: Suppose that Assumptions 1 and 2 hold. Then prevalence is sharply
bounded by
ρ ∈
[
γ
pi
× pi + (κ− 1)τ(pi − γ)
κ(pi − γ) + γ ,
γ
pi
× pi + (κ− 1)τ(pi − γ)
κ(pi − γ) + γ
]
. (2.5)
including by the corresponding limiting expressions as κ→ −∞ or κ→∞. In particular, if
κ =∞ as in the empirical application, we have
ρ ∈
[
τγ
pi
,
γ
pi
× pi + (κ− 1)τ(pi − γ)
κ(pi − γ) + γ
]
. (2.6)
Proof. To keep algebra transparent, introduce new notation τc = Pr(T = 1|C = c). Write
γ =
Pr(R = 1|T = 1)
Pr(T = 1)
=
ρτ1pi
τ
=⇒ τ1 = γτ
ρpi
. (2.7)
Substituting
Pr(T = 1|C = 1)
1− Pr(T = 1|C = 1) = κ
Pr(T = 1|C = 0)
1− Pr(T = 1|C = 0) =⇒ τ0 =
τ1
τ1 + κ(1− τ1)
into the accounting identity τ = ρτ1 + (1− ρ)τ0 yields
τ = ρτ1 + (1− ρ) τ1
τ1 + κ(1− τ1) .
Substituting for τ1 from (2.7) and some rearranging of terms leads to
ρ =
γ
pi
× pi + (κ− 1)τ(pi − γ)
κ(pi − γ) + γ .
This expression decreases in both pi and κ, and bounds follow by evaluating this at (pi, κ) =
[5]
(pi, κ) respectively (pi, κ) = (pi, κ).
Note that these bounds effectively multiply sample prevalence by an adjustment factor
that reflects test selectivity. As would be expected, the implied ρ decreases in κ and pi.
Note also (again as expected) that the adjustment factor simplifies to ρ = γ/pi at κ = 1 (no
selectivity would mean we estimate prevalence by prevalence in the tested subpopulation),
to ρ = τγ/pi as κ → ∞ (perfect targeting means we impute zero prevalence in the untested
population; compare (2.6)) and also, for the record, ρ = 1 − τ + τγ/pi as κ → 0 (perfectly
wrong targeting means we impute complete prevalence in the untested population).
Remark 2.2: Propositions 1 and 2 are separable in their effects on bounds: The first one
restricts the relation between test yield and prevalence in the tested population, the second
one restricts prevalence across tested and untested populations. Readers are encouraged to
“pick and choose” and, of course, also to propose other approaches. For example, sensitivity
adjustment could be combined with MM’s suggestion to restrict the rate of asymptomatic
infections.
2.3 Bounds on the Negative Predictive Value
The negative predictive value NPV = Pr(C = 0|R = 0, T = 1) is the probability that a
negative test result is accurate. It is of great importance in medical decision making (Eng
and Bluemke, 2020; Manski, 2020; Watson et al., 2020). It can be bounded as follows:
Proposition 3: Suppose Assumption 1 holds. Then sharp bounds on the NPV η =
Pr(C = 0|R = 0, T = 1) are given by
η ∈
[
pi − γ
pi − piγ ,
pi − γ
pi − piγ
]
. (2.8)
Proof. Write
η =
Pr(C = 0, R = 0|T = 1)
Pr(C = 0, R = 0|T = 1) + Pr(C = 1, R = 0|T = 1)
=
1− Pr(C = 1|T = 1)
1− Pr(C = 1|T = 1) + (1− pi) Pr(C = 1|T = 1) =
1− γ/pi
1− γ/pi + (1− pi)γ/pi ,
where γ = piPr(C = 1|T = 1) was used. The expression can be simplified and is easily seen
to be decreasing in pi.
This result could again be easily generalized to also allow for specificity of less than 1.
In that case, there would also be nondegenerate bounds on the positive predictive value
Pr(C = 1|R = 1, T = 1), which equals 1 here because of the assumption of perfect specificity.
[6]
2.4 Comparison to Bounds that Start from NPV
Assumption 1 contrasts with MM’s strategy of inputting ex ante bounds on the NPV. In
each case, bounds on the respective other quantity become an output of the model, so the
direction of logical inference is reversed. Notating the input bounds as η ∈ [η, η], the direct
comparable to (2.6) is
ρ ∈ [τ(γ + (1− γ)η), γ + (1− γ)η]. (2.9)
The following are some methodological considerations as to why one might want to start from
sensitivity and selectivity.
• By bounding the NPV, one necessarily directly bounds prevalence in the tested popu-
lation. This is because Pr(C = 1|T = 1) = γ + (1− γ)(1− η), so the lower and upper
bound on Pr(C = 1|T = 1) necessarily exceed the corresponding bound on (1 − η).
Since also the upper bound on overall prevalence is just the upper bound on prevalence
in the tested population, the effect can be large.
Consider MM’s prior bounds of [.6, .9] on the NPV. With this input, no data can move
the upper bound on prevalence below .4. For example, if test yield is .1, then prevalence
in the tested population is bounded by [.19, .46]; the upper bound of .46 also applies
to overall prevalence; and test sensitivity is concluded to have been in [.22, .53]. This
example is stark but not hypothetical; in fact, it is basically the first entry in Table 2
in MM (replicated in the first line of Table 1 below). About half of the upper bounds
in that table are below .5, so it is important to understand that they cannot be below
.4 by construction.2
In contrast, prior bounds on sensitivity do not directly imply anything about prevalence.
• Inputting sensitivity (and possibly specificity) generates an interface with the litera-
ture on diagnostic tests because that is what this literature focuses on. For a general
example, see Table 1 in Paules and Subbarao (2017). With regard to COVID-19, practi-
tioners’ guides (Eng and Bluemke, 2020; Watson et al., 2020) emphasize the importance
of NPV for decisions but treat sensitivity and specificity as scientific input and NPV
as jointly determined by those and prevalence. The literature on diagnostic testing
(Arevalo-Rodriguez et al., 2020; Yang et al., 2020) is explicitly about sensitivity.
MM seem to disagree when they write: “Medical experts have been cited as believing
that the rate of false-negative test findings is at least 0.3. However, it is not clear
whether they have in mind one minus the NPV or one minus test sensitivity.” The
technical definition of false-negative rate is not in doubt, so the concern is about in-
formal usage. This may be a valid point in general, especially as conflation of the two
2That bounds on NPV presuppose bounds on prevalence is clearly expressed in Manski (2020), who reverses
the direction of logical inference and bounds the NPV of serological tests by inputting MM’s prevalence bounds
which, in turn, inputted assumed (albeit for PCR tests) NPV bounds.
[7]
corresponds to base-rate neglect, but it did not occur to me with regard to the literature
on COVID-19.3
• The textbook view (Zhou et al., 2002, chapter 2) of sensitivity as technological constant
has been challenged (Leeflang et al., 2008). In the specific example, one could maybe
imagine that sensitivity and prevalence are related through the distribution of viral
load among the infected.
However, to justify the present analysis, it is not necessary that sensitivity be constant
or even unrelated to prevalence, as long as it is always within the input bounds. This
appears plausible enough, especially compared to the analogous restriction on NPV.
• Asserting bounds on NPV without taking targeting of tests into account may ignore
constraining information that could lead to tighter bounds. Specifically, relatively low
bounds on the NPV (i.e., asserting that a large fraction of negative test results are false)
will be more plausible if one believes the test to be efficiently targeted. But in that
same case one would conclude that the constraint Pr(C = 1|T = 1) ≥ Pr(C = 1|T = 0)
is far from binding. Therefore, the degree of targeting informally enters the bounds
twice, in different directions, but derivation of (2.9) does not force the value to be the
same in both appearances. Assumption 2 is intended to allow for targeting of tests to
affect bounds in a more disciplined manner.
3 Empirical Application
These bounds are mainly designed to process the information that is available early in a
pandemic. For this reason and to highlight some important differences, I first illustrate them
on MM’s data, i.e. daily counts of tests, test results, and fatalities for Illinois, New York, and
Italy in March and April.4 However, I also present some results for current hot spots.
The first two columns of Tables 1-3 bound prevalence based on the assumption that NPV
is in [.6, .9]. This replicates MM’s Table 2.5 The next two columns show implied bounds on
test sensitivity computed by inverting Proposition 3. The next two columns do not directly
restrict NPV, but restrict sensitivity to be in [.7, .95]. This is the sensitivity interval used
by Frazier et al. (2020) in the analysis on which Cornell’s Fall reopening plans are based,
3The footnote accompanying the cited sentence links to a news piece that attributes an estimated false-
negative rate of .3 to Yang et al. (2020). While the news piece has vague language, Yang et al. (2020)
unambiguously estimates one minus sensitivity.
4MM’s results were independently replicated from their original data. MATLAB code generating all tables
is available from the author.
5MM refine these bounds by imposing time monotonicity; that is, prevalence (and therefore both bounds
on it) cannot decrease over time. I agree with that restriction and can provide tables that implement it. It is
dropped here solely because those tables have many identical rows, obscuring some interesting comparisons.
[8]
and it corresponds to my reading of the literature.6 The final two columns show the implied
bounds on NPV. All bounds also impose that prevalence is larger in the tested compared to
the untested population.
The new upper bounds are considerably more restrictive and the lower bounds are slightly
less so, though the relative effect on lower bounds is occasionally quite large. In sum, all
bounds move down, and the dominating overall impression is one of tighter bounds. The
difference is frequently large – many upper bounds are reduced by more than half. It is also
meaningful. The new bounds would rather clearly have ruled out speculation of saturation
being “around the corner” at the time. Consider also the implied bounds on the infection
fatality rate (IFR). The most informative NPV-based lower bounds (i.e., evaluated on 4/24)
equal .0003 for Illinois, .0013 for New York, and .0010 for Italy, close to “flu-like” numbers
that were the subject of speculation. The comparison numbers for the novel bounds are
.0005, .0016, and .0026; for Italy, the lower bound is above .001 starting on 3/29. In places
where the data admittedly spoke very loudly, these numbers would have cast strong doubts
on “just the flu” conjectures in real time.
Of course, tighter bounds are an unambiguous improvement only if assumptions did not
become less credible. I would argue that this is the case here. The tables reveal that input
assumptions were barely compatible: The NPV-based bounds frequently imply sensitivity
below .7, and the sensitivity-based bounds imply NPV mostly close to, and frequently above,
.9. Which numbers are more convincing is obviously a judgment call. But the former number
seems out of step with expert opinion, including at the time, whereas the latter one would
probably not have raised any eyebrows.7 Also, Table 2 reveals that according to NPV-based
bounds, sensitivity increased in New York (the bounds fail to overlap). This might have
happened, but forcing it by assumption is arguably against the spirit of weak and credible
partial identification assumptions. I would contend that these observations corroborate my
main methodological qualm: Prior bounds on NPV depend on prior guesses of prevalence,
and it is difficult to get those right.
Table 4 repeats the exercise for data from current (as of 8/13) hot spots of the pandemic.8
I deliberately restrict attention to states with high test yield because it seems that MM
6UCSF (2020) base medical advice on a point estimate of .8. Watson et al. (2020) give .7 as “lower end of
current estimates from systematic reviews.” Frazier et al. (2020) use a preferred point estimate of .9.
7As part of a recent partial identification analysis, Sacks et al. (2020) provide an empirically informed
NPV estimate for Indiana of .995. This comes with caveats: It corresponds to obviously lower prevalence
than in the data considered here, so that MM would presumably have inputted different NPV bounds; also,
it operationalizes NPV as test-retest validity. UCSF (2020) gives NPV as .972 for symptomatic and .998 for
asymptomatic cases in the Bay Area, though using the sort of point-identifying assumptions that we seek to
avoid here.
8Test counts and results were retrieved from the COVID tracking project. State populations are U.S.
Census estimates for 7/1/19.
[9]
Using NPV to Bound... Using Sensitivity to Bound...
Date Prevalence Sensitivity Prevalence NPV
3/16 0.000 0.455 0.202 0.503 0.000 0.131 0.957 0.995
3/17 0.000 0.464 0.230 0.544 0.000 0.152 0.949 0.994
3/18 0.000 0.484 0.290 0.620 0.000 0.201 0.930 0.991
3/19 0.000 0.480 0.279 0.607 0.000 0.191 0.934 0.992
3/20 0.000 0.482 0.283 0.613 0.000 0.195 0.932 0.992
3/21 0.000 0.472 0.255 0.578 0.000 0.172 0.941 0.993
3/22 0.000 0.475 0.263 0.588 0.000 0.178 0.939 0.992
3/23 0.000 0.478 0.272 0.599 0.000 0.186 0.936 0.992
3/24 0.000 0.480 0.278 0.607 0.000 0.191 0.934 0.992
3/25 0.000 0.479 0.274 0.602 0.000 0.188 0.935 0.992
3/26 0.000 0.492 0.310 0.643 0.000 0.218 0.923 0.991
3/27 0.000 0.484 0.290 0.620 0.000 0.201 0.930 0.991
3/28 0.000 0.482 0.285 0.614 0.000 0.196 0.932 0.992
3/29 0.001 0.499 0.332 0.665 0.000 0.237 0.915 0.990
3/30 0.001 0.500 0.332 0.666 0.000 0.237 0.915 0.990
3/31 0.001 0.502 0.339 0.672 0.000 0.243 0.912 0.989
4/01 0.001 0.504 0.343 0.676 0.001 0.247 0.910 0.989
4/02 0.001 0.506 0.349 0.682 0.001 0.252 0.908 0.989
4/03 0.001 0.511 0.363 0.695 0.001 0.265 0.903 0.988
4/04 0.001 0.516 0.375 0.706 0.001 0.276 0.897 0.987
4/05 0.001 0.515 0.371 0.702 0.001 0.273 0.899 0.988
4/06 0.001 0.517 0.377 0.708 0.001 0.278 0.896 0.987
4/07 0.002 0.518 0.380 0.711 0.001 0.282 0.895 0.987
4/08 0.002 0.521 0.386 0.715 0.001 0.287 0.892 0.987
4/09 0.002 0.522 0.389 0.718 0.001 0.290 0.891 0.987
4/10 0.002 0.523 0.391 0.720 0.001 0.292 0.890 0.986
4/11 0.002 0.524 0.394 0.723 0.002 0.295 0.888 0.986
4/12 0.002 0.524 0.395 0.723 0.002 0.296 0.888 0.986
4/13 0.002 0.525 0.397 0.725 0.002 0.297 0.887 0.986
4/14 0.003 0.526 0.399 0.727 0.002 0.300 0.886 0.986
4/15 0.003 0.526 0.400 0.727 0.002 0.300 0.886 0.986
4/16 0.003 0.526 0.399 0.727 0.002 0.300 0.886 0.986
4/17 0.003 0.527 0.402 0.729 0.002 0.303 0.885 0.986
4/18 0.003 0.527 0.402 0.729 0.002 0.303 0.885 0.986
4/19 0.003 0.527 0.402 0.729 0.003 0.303 0.885 0.986
4/20 0.003 0.527 0.403 0.729 0.003 0.303 0.884 0.986
4/21 0.004 0.528 0.404 0.731 0.003 0.305 0.884 0.986
4/22 0.004 0.528 0.404 0.731 0.003 0.305 0.884 0.986
4/23 0.004 0.528 0.404 0.730 0.003 0.304 0.884 0.986
4/24 0.004 0.525 0.398 0.726 0.003 0.299 0.887 0.986
Table 1: Comparison of Bounds for Illinois. Only the direction of test selectivity is restricted.
The left-hand bounds input NPV ∈ [.6, .9], the right-hand bounds input sensitivity ∈ [.7, .95].
[10]
Using NPV to Bound... Using Sensitivity to Bound...
Date Prevalence Sensitivity Prevalence NPV
3/16 0.000 0.480 0.279 0.607 0.000 0.191 0.934 0.992
3/17 0.000 0.497 0.324 0.657 0.000 0.230 0.918 0.990
3/18 0.000 0.511 0.361 0.693 0.000 0.263 0.903 0.988
3/19 0.000 0.531 0.410 0.736 0.000 0.311 0.881 0.985
3/20 0.001 0.536 0.423 0.745 0.001 0.324 0.875 0.985
3/21 0.001 0.547 0.449 0.765 0.001 0.351 0.860 0.983
3/22 0.001 0.559 0.475 0.783 0.001 0.380 0.845 0.981
3/23 0.002 0.568 0.494 0.796 0.001 0.401 0.833 0.979
3/24 0.002 0.578 0.514 0.809 0.002 0.425 0.819 0.978
3/25 0.002 0.583 0.523 0.814 0.002 0.435 0.812 0.977
3/26 0.003 0.593 0.543 0.826 0.002 0.460 0.796 0.975
3/27 0.003 0.601 0.558 0.835 0.003 0.479 0.784 0.973
3/28 0.004 0.607 0.568 0.840 0.003 0.493 0.774 0.972
3/29 0.004 0.614 0.581 0.847 0.004 0.509 0.763 0.971
3/30 0.005 0.622 0.594 0.854 0.004 0.528 0.749 0.969
3/31 0.005 0.627 0.604 0.859 0.005 0.541 0.739 0.968
4/01 0.006 0.632 0.612 0.863 0.005 0.552 0.730 0.967
4/02 0.006 0.637 0.620 0.867 0.006 0.564 0.720 0.966
4/03 0.007 0.641 0.626 0.870 0.006 0.573 0.713 0.965
4/04 0.007 0.642 0.629 0.871 0.007 0.577 0.710 0.964
4/05 0.008 0.644 0.632 0.873 0.007 0.582 0.705 0.964
4/06 0.008 0.645 0.633 0.873 0.008 0.583 0.704 0.964
4/07 0.009 0.645 0.634 0.874 0.008 0.584 0.704 0.964
4/08 0.009 0.645 0.633 0.874 0.009 0.584 0.704 0.964
4/09 0.010 0.645 0.633 0.873 0.009 0.583 0.705 0.964
4/10 0.011 0.646 0.634 0.874 0.010 0.585 0.703 0.964
4/11 0.011 0.645 0.634 0.874 0.010 0.584 0.704 0.964
4/12 0.011 0.645 0.632 0.873 0.011 0.582 0.705 0.964
4/13 0.012 0.643 0.630 0.872 0.011 0.579 0.708 0.964
4/14 0.013 0.644 0.631 0.873 0.012 0.581 0.707 0.964
4/15 0.013 0.642 0.629 0.871 0.012 0.577 0.710 0.964
4/16 0.014 0.640 0.626 0.870 0.012 0.572 0.714 0.965
4/17 0.014 0.638 0.622 0.868 0.013 0.567 0.718 0.965
4/18 0.014 0.636 0.618 0.866 0.013 0.562 0.722 0.966
4/19 0.015 0.634 0.616 0.865 0.013 0.558 0.725 0.966
4/20 0.015 0.633 0.613 0.864 0.014 0.554 0.729 0.967
4/21 0.015 0.630 0.609 0.862 0.014 0.548 0.733 0.967
4/22 0.016 0.627 0.604 0.859 0.014 0.541 0.739 0.968
4/23 0.016 0.623 0.597 0.855 0.015 0.531 0.746 0.969
4/24 0.017 0.618 0.587 0.851 0.015 0.518 0.756 0.970
Table 2: Comparison of Bounds for New York. Only the direction of test selectivity
is restricted. The left-hand bounds input NPV ∈ [.6, .9], the right-hand bounds input
sensitivity ∈ [.7, .95].
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Using NPV to Bound... Using Sensitivity to Bound...
Date Prevalence Sensitivity Prevalence NPV
3/16 0.001 0.522 0.389 0.718 0.000 0.290 0.891 0.987
3/17 0.001 0.527 0.402 0.729 0.001 0.303 0.885 0.986
3/18 0.001 0.529 0.407 0.733 0.001 0.308 0.882 0.986
3/19 0.001 0.535 0.420 0.743 0.001 0.321 0.876 0.985
3/20 0.001 0.536 0.424 0.746 0.001 0.325 0.874 0.985
3/21 0.001 0.538 0.427 0.749 0.001 0.328 0.872 0.984
3/22 0.001 0.537 0.426 0.748 0.001 0.327 0.873 0.984
3/23 0.001 0.539 0.430 0.751 0.001 0.332 0.870 0.984
3/24 0.002 0.540 0.432 0.752 0.001 0.333 0.870 0.984
3/25 0.002 0.538 0.427 0.748 0.001 0.328 0.873 0.984
3/26 0.002 0.534 0.418 0.742 0.001 0.319 0.877 0.985
3/27 0.002 0.532 0.413 0.738 0.002 0.314 0.879 0.985
3/28 0.002 0.529 0.407 0.733 0.002 0.308 0.882 0.986
3/29 0.002 0.529 0.407 0.733 0.002 0.307 0.883 0.986
3/30 0.002 0.528 0.404 0.730 0.002 0.304 0.884 0.986
3/31 0.002 0.525 0.397 0.725 0.002 0.298 0.887 0.986
4/01 0.003 0.523 0.391 0.720 0.002 0.292 0.890 0.986
4/02 0.003 0.519 0.382 0.712 0.002 0.283 0.894 0.987
4/03 0.003 0.516 0.375 0.706 0.002 0.276 0.897 0.987
4/04 0.003 0.514 0.369 0.701 0.002 0.271 0.900 0.988
4/05 0.003 0.512 0.364 0.696 0.002 0.266 0.902 0.988
4/06 0.003 0.510 0.360 0.692 0.002 0.262 0.904 0.988
4/07 0.003 0.508 0.354 0.686 0.002 0.256 0.906 0.988
4/08 0.003 0.504 0.343 0.676 0.002 0.247 0.911 0.989
4/09 0.004 0.501 0.336 0.669 0.003 0.240 0.913 0.989
4/10 0.004 0.498 0.327 0.660 0.003 0.232 0.917 0.990
4/11 0.004 0.495 0.319 0.652 0.003 0.226 0.920 0.990
4/12 0.004 0.493 0.314 0.647 0.003 0.221 0.922 0.990
4/13 0.004 0.491 0.310 0.643 0.003 0.218 0.923 0.991
4/14 0.004 0.491 0.308 0.641 0.003 0.216 0.924 0.991
4/15 0.004 0.489 0.302 0.634 0.003 0.211 0.926 0.991
4/16 0.004 0.486 0.295 0.626 0.003 0.205 0.928 0.991
4/17 0.005 0.483 0.287 0.617 0.003 0.198 0.931 0.992
4/18 0.005 0.481 0.280 0.609 0.003 0.192 0.933 0.992
4/19 0.005 0.479 0.275 0.603 0.003 0.188 0.935 0.992
4/20 0.005 0.478 0.271 0.598 0.003 0.185 0.936 0.992
4/21 0.005 0.476 0.266 0.592 0.003 0.181 0.938 0.992
4/22 0.005 0.474 0.261 0.586 0.003 0.177 0.939 0.993
4/23 0.005 0.472 0.255 0.577 0.003 0.172 0.941 0.993
4/24 0.006 0.471 0.250 0.571 0.003 0.168 0.943 0.993
Table 3: Comparison of Bounds for Italy. Only the direction of test selectivity is restricted.
The left-hand bounds input NPV ∈ [.6, .9], the right-hand bounds input sensitivity ∈ [.7, .95].
[12]
Using NPV to Bound... Using Sensitivity to Bound...
State Prevalence Sensitivity Prevalence NPV
Arizona 0.038 0.508 0.355 0.687 0.028 0.258 0.906 0.988
California 0.037 0.438 0.143 0.401 0.016 0.090 0.971 0.996
Florida 0.043 0.481 0.281 0.610 0.027 0.193 0.933 0.992
Illinois 0.040 0.437 0.142 0.399 0.017 0.089 0.972 0.997
New Jersey 0.046 0.447 0.174 0.457 0.022 0.111 0.964 0.996
New York 0.055 0.437 0.142 0.398 0.023 0.089 0.972 0.997
Texas 0.031 0.473 0.257 0.580 0.019 0.173 0.941 0.993
Table 4: Extension of previous tables to some pandemic hot spots (as of 8/13).
calibrated their input bounds to such places. NPV-based bounds continue to allow for very
high prevalence but also force test sensitivity to be relatively low. Sensitivity-based upper
bounds are at most half – often much less – than their NPV-based counterparts, and other
implications of respective bounds are roughly as before. This comes with a caveat: As the
pandemic progresses, credible bounds should differentiate between current and past infection
and account for repeat tests. I leave these extensions to future research and emphasize that
Table 4 is meant to be illustrative, especially with regard to “first wave” hot spots.
Tables 5-7 show the effect of increasingly restricting test selectivity through Assumption
2. The tables start with κ = 1, i.e. test monotonicity, and progress through arguably weak
restrictions up to κ = 5, which is restrictive and may be more in the spirit of a sensitivity
parameter. Upper bounds respond strongly. This is reflected in the implied lower bounds
on the IFR; for Italy, these increase to (in order) .0036, .0046, .0065, and .0102. Of course,
these numbers should not be compared to MM’s Table 3; to the contrary, MM reach similar
conclusions when restricting the proportion of asymptomatic infections. The same exercise
but for current hot spots is displayed in Table 8.
The lower bounds are driven by the possibility that all true positives got tested. While
this paper focuses on upper bounds, one could also use Assumption 2 to refine lower bounds
away from that scenario. For the record, restricting κ ≤ 100 [κ ≤ 10] would refine the (last
period) lower bound on prevalence for Italy from .0034 to .0047 [.0325]. The upper bound on
IFR would be refined from .1278 to .0908 [.0132], a not completely vacuous restriction.
I omit inference on the bounds. In general, such inference has at least two nonstandard
aspects: As MM point out, one might think of states and regions as populations of interest
rather than samples from meta-populations; at the very least, one might be interested in in-
ference conditionally on the realized population. In that sense, conventional sampling theory
might not apply. However, whether a given subject is tested and the result of that test are
Bernoulli random variables, opening a clear avenue for statistical inference. Separately, such
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Lower Upper Bounds with:
Date Bounds κ ≥ 5 κ ≥ 3 κ ≥ 2 κ ≥ 1.5 κ ≥ 1
3/16 0.000 0.036 0.048 0.070 0.091 0.131
3/17 0.000 0.043 0.057 0.082 0.107 0.152
3/18 0.000 0.059 0.077 0.111 0.143 0.201
3/19 0.000 0.056 0.073 0.106 0.136 0.191
3/20 0.000 0.057 0.075 0.108 0.139 0.195
3/21 0.000 0.049 0.065 0.094 0.122 0.172
3/22 0.000 0.052 0.068 0.098 0.127 0.178
3/23 0.000 0.054 0.071 0.102 0.132 0.186
3/24 0.000 0.056 0.073 0.106 0.136 0.191
3/25 0.000 0.055 0.072 0.104 0.133 0.188
3/26 0.000 0.065 0.085 0.122 0.157 0.218
3/27 0.000 0.059 0.077 0.112 0.143 0.201
3/28 0.000 0.058 0.075 0.109 0.140 0.196
3/29 0.000 0.072 0.094 0.134 0.171 0.237
3/30 0.000 0.073 0.094 0.135 0.172 0.237
3/31 0.000 0.075 0.097 0.139 0.177 0.243
4/01 0.001 0.076 0.099 0.141 0.180 0.247
4/02 0.001 0.078 0.101 0.144 0.183 0.252
4/03 0.001 0.083 0.108 0.153 0.194 0.265
4/04 0.001 0.088 0.114 0.161 0.203 0.276
4/05 0.001 0.087 0.112 0.158 0.200 0.273
4/06 0.001 0.089 0.115 0.162 0.205 0.278
4/07 0.001 0.090 0.116 0.165 0.208 0.282
4/08 0.001 0.093 0.119 0.168 0.212 0.287
4/09 0.001 0.094 0.121 0.170 0.215 0.290
4/10 0.001 0.095 0.122 0.172 0.216 0.292
4/11 0.002 0.096 0.124 0.174 0.219 0.295
4/12 0.002 0.097 0.124 0.174 0.219 0.296
4/13 0.002 0.097 0.125 0.176 0.221 0.297
4/14 0.002 0.099 0.127 0.178 0.223 0.300
4/15 0.002 0.099 0.127 0.178 0.223 0.300
4/16 0.002 0.099 0.127 0.178 0.223 0.300
4/17 0.002 0.100 0.128 0.180 0.225 0.303
4/18 0.002 0.100 0.129 0.180 0.226 0.303
4/19 0.003 0.100 0.128 0.180 0.225 0.303
4/20 0.003 0.101 0.129 0.180 0.226 0.303
4/21 0.003 0.101 0.130 0.181 0.227 0.305
4/22 0.003 0.102 0.130 0.182 0.228 0.305
4/23 0.003 0.101 0.130 0.181 0.227 0.304
4/24 0.003 0.099 0.127 0.177 0.222 0.299
Table 5: Change in bounds for Illinois as test selectivity is increasingly restricted.
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Lower Upper Bounds with:
Date Bounds κ ≥ 5 κ ≥ 3 κ ≥ 2 κ ≥ 1.5 κ ≥ 1
3/16 0.000 0.056 0.073 0.106 0.136 0.191
3/17 0.000 0.070 0.091 0.130 0.166 0.230
3/18 0.000 0.082 0.107 0.152 0.193 0.263
3/19 0.000 0.102 0.131 0.184 0.231 0.311
3/20 0.001 0.107 0.138 0.193 0.242 0.324
3/21 0.001 0.120 0.153 0.213 0.265 0.351
3/22 0.001 0.134 0.170 0.235 0.290 0.380
3/23 0.001 0.144 0.183 0.251 0.309 0.401
3/24 0.002 0.157 0.199 0.270 0.330 0.425
3/25 0.002 0.163 0.206 0.279 0.340 0.435
3/26 0.002 0.178 0.223 0.300 0.363 0.460
3/27 0.003 0.189 0.236 0.316 0.381 0.479
3/28 0.003 0.198 0.247 0.329 0.394 0.493
3/29 0.004 0.209 0.259 0.343 0.410 0.509
3/30 0.004 0.222 0.274 0.360 0.428 0.528
3/31 0.005 0.231 0.285 0.373 0.441 0.541
4/01 0.005 0.240 0.295 0.384 0.452 0.552
4/02 0.006 0.249 0.305 0.395 0.464 0.564
4/03 0.006 0.256 0.313 0.404 0.473 0.573
4/04 0.007 0.259 0.316 0.408 0.478 0.577
4/05 0.007 0.264 0.321 0.413 0.483 0.582
4/06 0.008 0.265 0.323 0.415 0.485 0.583
4/07 0.008 0.266 0.324 0.416 0.485 0.584
4/08 0.009 0.266 0.324 0.415 0.485 0.584
4/09 0.009 0.266 0.323 0.415 0.484 0.583
4/10 0.010 0.268 0.325 0.417 0.486 0.585
4/11 0.010 0.267 0.325 0.416 0.486 0.584
4/12 0.011 0.267 0.324 0.415 0.484 0.582
4/13 0.011 0.264 0.321 0.412 0.481 0.579
4/14 0.012 0.266 0.323 0.414 0.483 0.581
4/15 0.012 0.263 0.320 0.410 0.479 0.577
4/16 0.012 0.260 0.316 0.406 0.474 0.572
4/17 0.013 0.256 0.312 0.401 0.469 0.567
4/18 0.013 0.253 0.308 0.396 0.464 0.562
4/19 0.013 0.250 0.305 0.392 0.460 0.558
4/20 0.014 0.247 0.301 0.389 0.456 0.554
4/21 0.014 0.244 0.297 0.384 0.451 0.548
4/22 0.014 0.239 0.291 0.377 0.443 0.541
4/23 0.015 0.232 0.284 0.368 0.434 0.531
4/24 0.015 0.224 0.274 0.357 0.422 0.518
Table 6: Change in bounds for New York as test selectivity is increasingly restricted.
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Lower Upper Bounds with:
Date Bounds κ ≥ 5 κ ≥ 3 κ ≥ 2 κ ≥ 1.5 κ ≥ 1
3/16 0.000 0.093 0.120 0.170 0.214 0.290
3/17 0.001 0.098 0.127 0.179 0.225 0.303
3/18 0.001 0.101 0.130 0.183 0.229 0.308
3/19 0.001 0.106 0.137 0.191 0.240 0.321
3/20 0.001 0.108 0.139 0.194 0.243 0.325
3/21 0.001 0.110 0.141 0.197 0.246 0.328
3/22 0.001 0.109 0.140 0.196 0.245 0.327
3/23 0.001 0.111 0.143 0.199 0.249 0.332
3/24 0.001 0.112 0.143 0.200 0.250 0.333
3/25 0.001 0.110 0.141 0.197 0.246 0.328
3/26 0.001 0.106 0.136 0.190 0.238 0.319
3/27 0.002 0.104 0.133 0.187 0.234 0.314
3/28 0.002 0.101 0.130 0.183 0.229 0.308
3/29 0.002 0.101 0.130 0.183 0.229 0.307
3/30 0.002 0.100 0.129 0.181 0.227 0.304
3/31 0.002 0.098 0.125 0.176 0.221 0.298
4/01 0.002 0.095 0.122 0.172 0.216 0.292
4/02 0.002 0.092 0.118 0.166 0.209 0.283
4/03 0.002 0.089 0.115 0.161 0.204 0.276
4/04 0.002 0.087 0.112 0.158 0.199 0.271
4/05 0.002 0.085 0.110 0.155 0.196 0.266
4/06 0.002 0.084 0.108 0.152 0.193 0.262
4/07 0.002 0.082 0.105 0.148 0.188 0.256
4/08 0.002 0.078 0.100 0.142 0.180 0.247
4/09 0.003 0.076 0.097 0.138 0.175 0.240
4/10 0.003 0.073 0.094 0.133 0.169 0.232
4/11 0.003 0.070 0.091 0.129 0.164 0.226
4/12 0.003 0.069 0.089 0.126 0.160 0.221
4/13 0.003 0.068 0.087 0.124 0.158 0.218
4/14 0.003 0.067 0.087 0.123 0.156 0.216
4/15 0.003 0.065 0.084 0.120 0.153 0.211
4/16 0.003 0.063 0.082 0.116 0.148 0.205
4/17 0.003 0.061 0.079 0.112 0.142 0.198
4/18 0.003 0.059 0.076 0.108 0.138 0.192
4/19 0.003 0.058 0.074 0.106 0.135 0.188
4/20 0.003 0.057 0.073 0.104 0.133 0.185
4/21 0.003 0.056 0.071 0.102 0.130 0.181
4/22 0.003 0.054 0.070 0.099 0.127 0.177
4/23 0.003 0.053 0.067 0.096 0.123 0.172
4/24 0.003 0.051 0.066 0.094 0.120 0.168
Table 7: Change in bounds for Italy as test selectivity is increasingly restricted.
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Lower Upper Bounds with:
State Bounds κ ≥ 5 κ ≥ 3 κ ≥ 2 κ ≥ 1.5 κ ≥ 1
Arizona 0.028 0.093 0.126 0.164 0.198 0.258
California 0.016 0.036 0.046 0.057 0.068 0.090
Florida 0.027 0.074 0.097 0.123 0.148 0.193
Illinois 0.017 0.037 0.046 0.057 0.068 0.089
New Jersey 0.022 0.048 0.059 0.073 0.086 0.111
New York 0.023 0.044 0.052 0.061 0.071 0.089
Texas 0.019 0.060 0.081 0.106 0.130 0.173
Table 8: Change in bounds for current pandemic hot spots as test selectivity is restricted.
inference might in principle be about very small probabilities, so that straightforward (boot-
strap or normal approximation based) delta method approaches would not apply. Questions
like this inform an exciting strand of current research (Rothe, 2020; Toulis, 2020). They are
orthogonal to the thrust of this paper and also less salient in the application because the
massive sample sizes (i) would presumably justify normal or bootstrap approximation after
all and (ii) mean that identification dominates estimation as source of uncertainty.
4 Conclusion
This paper proposes new methods to bound prevalence of a disease from partially identifying
data and assumptions. It is mainly intended as “think piece” to alert researchers to the
possibly fruitful application of partial identification methods. I have no doubt that domain
knowledge may inform further, and better, iterations.
The conceptual innovation is to think of test accuracy as (unknown, not necessarily con-
stant, and possibly not even identifiable) technological parameter and of test selectivity as
something that econometric or epidemiological models can speak to. Bounds are therefore
constructed with these as starting points, deriving bounds on the NPV by implication and
not imposing any prior bound on prevalence in the tested population. In the empirical appli-
cation, it turns out that some of the more audacious speculations floated at the time were at
tension with credible partial identification analysis even then. This illustrates the potential
utility of such analysis in early stages of a pandemic.
At the current, more advanced stage of the pandemic, certain simplifications used in this
paper are a stretch. Notably, I would want to distinguish between current and past infection.
I leave the careful development of such bounds to future work, but would recommend to use
restrictions on test sensitivity as primitive of the analysis. Once again, my main hope is to
get the ball rolling.
[17]
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